TEVA•benzinga•
B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Lowers Price Target to $20
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 6, 2025 by benzinga